Chronic Kidney Disease and Lipid Disorders

Area of Science:

• Nephrology
• Cardiology
• Clinical Chemistry

Background:

• Chronic kidney disease (CKD) is a global health concern with increasing incidence and prevalence.
• CKD patients face high morbidity and mortality from cardiovascular disease (CVD).
• Dyslipidemia is a significant risk factor for CVD, underscoring the need to study lipid metabolism in CKD.

Purpose of the Study:

• To evaluate the lipid status of patients diagnosed with chronic kidney disease.
• To assess how lipid profiles change across different stages of CKD.

Main Methods:

• A one-year prospective study involving 150 adult patients with CKD stages I-IV.
• Creatinine clearance estimated using the Cockcroft-Goult formula.
• Patient staging based on Kidney Disease Outcomes Quality Initiative (K/DOQI) criteria.

Main Results:

• Average serum cholesterol levels showed variability, being highest in stage II and lowest in stage IV CKD.
• Average triglyceride levels exhibited a slight increase across CKD stages.
• Triglyceride levels were lowest in stage I and highest in stage III CKD patients.

Conclusions:

• Serum cholesterol levels did not change significantly with CKD progression.
• A nearly linear increase in average triglyceride levels was observed as CKD advanced.
• Triglyceride levels begin rising in early CKD stages, peaking in stage IV.